Basilea Pharmaceutica AG (BPMUF)

44,45 0,00 (0,00%) Börsenschluss: 01:56PM EDT

Basilea Pharmaceutica AG

Hegenheimermattweg 167b
Allschwil 4123
Switzerland
41 61 606 11 11
https://www.basilea.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 147

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. David Veitch	Chief Executive Officer	1,25M	N/A	1965
Mr. Adesh Kaul	Chief Financial Officer	N/A	N/A	1974
Dr. Gerrit Hauck Ph.D.	Chief Technology Officer	N/A	N/A	1964
Dr. Laurenz Kellenberger Ph.D.	Chief Scientific Officer	N/A	N/A	1967
Dr. Marc Engelhardt M.D.	Chief Medical Officer	N/A	N/A	1964
Dr. Peer Nils Schroder	Head of Corporate Communications & Investor Relations	N/A	N/A	N/A
Mr. Damian Heller	General Counsel & Corporate Secretary	N/A	N/A	1966
Mr. Andreas Kumin	Head of Corporate Development	N/A	N/A	N/A
Ms. Ursula Eberhardt	Head of Global Human Resources	N/A	N/A	1962
Mr. Mark Jones	Head of Project Management & Preclinical Development	N/A	N/A	1968

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.

Corporate Governance

Basilea Pharmaceutica AGs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.